newsfilter
← Latest News
GlobeNewswire·

Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®

AHZANTIVE® (aflibercept) is an EMA-approved biosimilar to Eylea® (aflibercept) with demonstrated similarity in efficacy, safety and immunogenicity to the reference product The launch expands Teva's biosimilars